Community Schedule

Enter at least 4 characters

3 results showing for: 'emtricitabine'

  1. Nucleosides Reverse Transcriptase Inhibitors
Efavirenz with emtricitabine and tenofovir disoproxil    Medsafe Data Sheets   New Zealand Formulary.   Hospital Medicines List.   PDF Schedule - Refer from page 115.
- Special Authority SA2139 [PDF] -- Retail pharmacy
  • Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate)
    • Brand Fully subsidised brand. Viatris
    • Pharmacode2644967
    • Subsidy $106.88
    • Measure / Qty per 30
SA2139 – Antiretrovirals [PDF]

Note: Efavirenz with emtricitabine and tenofovir disoproxil counts as three anti-retroviral medications for the purposes of the anti-retroviral Special Authority

  1. Nucleosides Reverse Transcriptase Inhibitors
Emtricitabine    Medsafe Data Sheets   New Zealand Formulary.   Hospital Medicines List.   PDF Schedule - Refer from page 115.
- Special Authority SA2139 [PDF] -- Retail pharmacy
  • Cap 200 mg
    • Brand Fully subsidised brand. Emtriva
    • Pharmacode2250063
    • Subsidy $307.20
    • Measure / Qty per 30
SA2139 – Antiretrovirals [PDF]
  1. HIV Prophylaxis and Treatment
Emtricitabine with tenofovir disoproxil    Medsafe Data Sheets   New Zealand Formulary.   Hospital Medicines List.   PDF Schedule - Refer from page 112.
- Subsidy by endorsement ; can be waived by Special Authority SA2138 [PDF]
  • 3 to 6 month supply. Tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a maleate)
    • Brand Fully subsidised brand. Tenofovir Disoproxil Emtricitabine Viatr
    • Pharmacode2638088
    • Subsidy $15.45
    • Measure / Qty per 30
  • 3 to 6 month supply. Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)
    • Brand Fully subsidised brand. Teva
    • Pharmacode2560488
    • Subsidy $15.45
    • Measure / Qty per 30
SA2138 – Emtricitabine with tenofovir disoproxil [PDF]

Funding for emtricitabine with tenofovir disoproxil for use as PrEP, should be applied using Special Authority SA2138.

Endorsement for treatment of conditions approved via Special Authority SA2139 (antiretrovirals for confirmed HIV, prevention of maternal transmission, post-exposure prophylaxis following exposure to HIV and percutaneous exposure): Prescription is deemed to be endorsed if emtricitabine with tenofovir disoproxil is co-prescribed with another antiretroviral subsidised under Special Authority SA2139 and the prescription is annotated accordingly by the Pharmacist or endorsed by the prescriber.

Note:

Emtricitabine with tenofovir disoproxil prescribed under endorsement, for treatment of conditions approved via Special Authority SA2139 (antiretrovirals for confirmed HIV, prevention of maternal transmission, post-exposure prophylaxis following exposure to HIV and percutaneous exposure), is included in the count of up to 4 subsidised antiretrovirals, and counts as two antiretroviral medications, for the purposes of Special Authority SA2139, page 1

There is an approval process to become a named specialist to prescribe antiretroviral therapy in New Zealand. Further information is available on the Pharmac website.

For eye preparations refer to Eye Preparations, Anti-Infective Preparations, page 269

  • Rectangle page icon symoblising a PDF. PDF
  • A tick icon. Fully subsidised
  • An oval with the number 29 in it. Unapproved medicine under Section 29
  • An asterisk symbol. 3 or 6 months should be dispensed at once
  • Two duplicate pages icon. Click to copy
  • A triangle symbol. Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.
  • OP Original pack
  • Sole Subsidised Supply



Email enquiry@pharmac.govt.nz to provide feedback: compliments, suggestions and complaints.